Journal of Medicine and Life Science

  • 제18권3호
  • /
  • Pages.49-55
  • /
  • 2021
  • /
  • 1738-1010(pISSN)
  • /
  • 2671-4922(eISSN)
제주대학교 의과학연구소 (Institute for Medical Science)
권호 표지
DOI QR코드

DOI QR Code

비정형 항정신병약제가 비만과 당대사에 미치는 영향

The Effect of Atypical Anti-psychotic Agents on Obesity and Glucose Metabolism

  • 이상아 (제주대학교 의과대학 제주대학교병원 내과) ;
  • 조석주 (제주대학교 의과대학 제주대학교병원 내과) ;
  • 문재철 (제주한라병원 내분비내과)
  • Sang Ah Lee (Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine) ;
  • Suk Ju Cho (Department of Internal Medicine, Jeju National University Hospital, Jeju National University College of Medicine) ;
  • Jae Cheol Moon (Division of Endocrinology and Metabolism, Department of Internal Medicine, Cheju Halla General Hospital)
  • 투고 : 2021.08.04
  • 심사 : 2021.12.05
  • 발행 : 2021.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Atypical antipsychotics are more effective than typical antipsychotics and have fewer side effects such as tardive dyskinesia and extrapyramidal symptoms; therefore, prescriptions of atypical antipsychotics are increasing. However, recently, it has been reported that atypical antipsychotics have a higher incidence of diabetes, hyperglycemia, and obesity than typical antipsychotics. Atypical antipsychotics induce obesity-inhibiting appetite-related receptors such as serotonin and dopamine. Decreased exercise due to improving psychotic symptoms, and genetic characterictics can also cause weight gain. Hyperglycemia and hypoglycemia were another metabolic problem related to treatment with atypical antipsychotics. The mechanisms of hyperglycemia were mainly related obesity, decreased anorexigenic hormones, and increased insulin resistance in multiple organs. There are also reports that genes related to diabetes have an effect on the incidence of diabetes mellitus treated with atypical antipsychotics. On the other hand, although it is not clear why hypoglycemia occurs, it documented in case reports all over the world. There are more reports of atypical antipsychotics than typical antipsychotics and these are frequently reported in Asians. Further research on the mechanism of hypoglycemia related to atypical antipsychotics is strongly recommended.

키워드

과제정보

This work was supported by the 2021 education, research and student guidance grant funded by Jeju National University.

참고문헌

  1. Kapur S, Remington G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001;52:503-17. 
  2. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007;18:39-60. 
  3. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999;60 Suppl 12:22-3. 
  4. Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56:1-10. 
  5. Umbricht DS, Wirshing WC, Wirshing DA, McMeniman M, Schooler NR, Marder SR, et al. Clinical predictors of response to clozapine treatment in ambulatory patients with schizophrenia. J Clin Psychiatry 2002;63:420-4. 
  6. Cohen SA. Successful clozapine rechallenge following prior intolerance to clozapine. J Clin Psychiatry 1994;55:498-9. 
  7. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63. 
  8. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999;60:107-15. 
  9. Drake RE, Mueser KT. Psychosocial approaches to dual diagnosis. Schizophr Bull 2000;26:105-18. 
  10. Gareri P, De Fazio P, Manfredi VG, De Sarro G. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol 2014;34:109-23. 
  11. Prommer E. Aripiprazole. Am J Hosp Palliat Care 2017;34:180-5. 
  12. Maneeton N, Maneeton B, Woottiluk P, Likhitsathian S, Suttajit S, Boonyanaruthee V, et al. Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2016;10:259-76. 
  13. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007;68 Suppl 4:8-13. 
  14. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. 
  15. Hirsch L, Yang J, Bresee L, Jette N, Patten S, Pringsheim T. Second-generation antipsychotics and metabolic side effects: a systematic review of population-based studies. Drug Saf 2017;40:771-81. 
  16. Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415-27. 
  17. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73. 
  18. DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52-77. 
  19. Giskes K, Avendano M, Brug J, Kunst AE. A systematic review of studies on socioeconomic inequalities in dietary intakes associated with weight gain and overweight/obesity conducted among European adults. Obes Rev 2010;11:413-29. 
  20. Chen A, Park TY, Li KJ, DeLisi LE. Antipsychotics and the microbiota. Curr Opin Psychiatry 2020;33:225-30. 
  21. Coccurello R, Moles A. Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 2010;127:210-51. 
  22. Petrik NG , Kimmel GA . Electron-stimulated reactions in nanoscale water films adsorbed on α-Al2O3(0001). Phys Chem Chem Phys 2018;20:11634-42. 
  23. Huang XF, Weston-Green K, Yu Y. Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity. Obes Rev 2018;19:396-405. 
  24. Aringhieri S, Carli M, Kolachalam S, Verdesca V, Cini E, Rossi M, et al. Molecular targets of atypical antipsychotics: from mechanism of action to clinical differences. Pharmacol Ther 2018;192:20-41. 
  25. Wan XQ, Zeng F, Huang XF, Yang HQ, Wang L, Shi YC, et al. Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway. CNS Neurosci Ther 2020;26:558-66. 
  26. Li L, Yoo ES, Li X, Wyler SC, Chen X, Wan R, et al. The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. J Exp Med 2021;218:e20202484.
  27. Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 2001;24:59-73. 
  28. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes 2017;8:390-6. 
  29. Singh R, Bansal Y, Medhi B, Kuhad A. Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives. Eur J Pharmacol 2019;844:231-40. 
  30. Koro CE, Fedder DO, L'Italien GJ, Weiss SS, Magder LS, Kreyenbuhl J, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325:243. 
  31. Mir S, Taylor D. Atypical antipsychotics and hyperglycaemia. Int Clin Psychopharmacol 2001;16:63-73. 
  32. Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature. Pharmacopsychiatry 2004;37:1-11. 
  33. Erle G, Basso M, Federspil G, Sicolo N, Scandellari C. Effect of chlorpromazine on blood glucose and plasma insulin in man. Eur J Clin Pharmacol 1977;11:15-8. 
  34. Gareri P, Segura-Garcia C, Manfredi VG, Bruni A, Ciambrone P, Cerminara G, et al. Use of atypical antipsychotics in the elderly: a clinical review. Clin Interv Aging 2014;9:1363-73. 
  35. Buse JB, Cavazzoni P, Hornbuckle K, Hutchins D, Breier A, Jovanovic L. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol 2003;56:164-70. 
  36. Wirshing DA, Bartzokis G, Pierre JM, Wirshing WC, Sun A, Tishler TA, et al. Tardive dyskinesia and serum iron indices. Biol Psychiatry 1998;44:493-8. 
  37. Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001;35:563-5. 
  38. Koller EA, Weber J, Doraiswamy PM, Schneider BS. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857-63. 
  39. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176:627-32. 
  40. Trifiro G, Spina E, Gambassi G. Use of antipsychotics in elderly patients with dementia: do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009;59:1-12. 
  41. Gill SS, Rochon PA, Herrmann N, Lee PE, Sykora K, Gunraj N, et al. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 2005;330:445. 
  42. Liperoti R, Gambassi G, Lapane KL, Chiang C, Pedone C, Mor V, et al. Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics. J Clin Psychiatry 2005;66:1090-6. 
  43. Fleischhacker WW, Siu CO, Boden R, Pappadopulos E, Karayal ON, Kahn RS. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial. Int J Neuropsychopharmacol 2013;16:987-95. 
  44. Sekine Y, Minabe Y, Ouchi Y, Takei N, Iyo M, Nakamura K, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 2003;160:1699-701. 
  45. Paris RM, Bedno SA, Krauss MR, Keep LW, Rubertone MV. Weighing in on type 2 diabetes in the military: characteristics of U.S. military personnel at entry who develop type 2 diabetes. Diabetes Care 2001;24:1894-8. 
  46. Bishara A, Phan SV, Young HN, Liao TV. Glucose disturbances and atypical antipsychotic use in the intensive care unit. J Pharm Pract 2016;29:534-8. 
  47. Fagerholm V, Haaparanta M, Scheinin M. α2-adrenoceptor regulation of blood glucose homeostasis. Basic Clin Pharmacol Toxicol 2011;108:365-70. 
  48. Farino ZJ, Morgenstern TJ, Maffei A, Quick M, De Solis AJ, Wiriyasermkul P, et al. New roles for dopamine D2 and D3 receptors in pancreatic beta cell insulin secretion. Mol Psychiatry 2020;25:2070-85. 
  49. Tudhope SJ, Wang CC, Petrie JL, Potts L, Malcomson F, Kieswich J, et al. A novel mechanism for regulating hepatic glycogen synthesis involving serotonin and cyclin-dependent kinase-5. Diabetes 2012;61:49-60. 
  50. Eftekhari A, Azarmi Y, Parvizpur A, Eghbal MA. Involvement of oxidative stress and mitochondrial/lysosomal cross-talk in olanzapine cytotoxicity in freshly isolated rat hepatocytes. Xenobiotica 2016;46:369-78. 
  51. Eftekhari A, Ahmadian E, Azarmi Y, Parvizpur A, Hamishehkar H, Eghbal MA. In vitro/vivo studies towards mechanisms of risperidone-induced oxidative stress and the protective role of coenzyme Q10 and N-acetylcysteine. Toxicol Mech Methods 2016;26:520-8. 
  52. Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genomics 2013;6 Suppl 1(Suppl 1):S17. 
  53. Davoudi M, Vijeepallam K, Azizi H, Mirnajafi-Zadeh J, Semnanian S. PKC inhibitor reversed the suppressive effect of orexin-A on IPSCs of locus coeruleus neurons in naloxone-induced morphine withdrawal. J Neural Transm (Vienna) 2019;126:1425-35. 
  54. Cao H, Chen J, Meyer-Lindenberg A, Schwarz E. A polygenic score for schizophrenia predicts glycemic control. Transl Psychiatry 2017;7:1295. 
  55. Brandl EJ, Tiwari AK, Lett TA, Shaikh SA, Lieberman JA, Meltzer HY, et al. Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. Hum Psychopharmacol 2013;28:183-7. 
  56. Szekeres F, Chadt A, Tom RZ, Deshmukh AS, Chibalin AV, Bjornholm M, et al. The Rab-GTPase-activating protein TBC1D1 regulates skeletal muscle glucose metabolism. Am J Physiol Endocrinol Metab 2012;303:E524-33. 
  57. Grajales D, Ferreira V, Valverde AM. Second-generation antipsychotics and dysregulation of glucose metabolism: beyond weight gain. Cells 2019;8:1336. 
  58. Guenette MD, Hahn M, Cohn TA, Teo C, Remington GJ. Atypical antipsychotics and diabetic ketoacidosis: a review. Psychopharmacology (Berl) 2013;226:1-12. 
  59. Henderson DC, Cagliero E, Copeland PM, Louie PM, Borba CP, Fan X, et al. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. J Clin Psychiatry 2007;68:533-41. 
  60. Nagamine T. Hypoglycemia associated with insulin hypersecretion following the addition of olanzapine to conventional antipsychotics. Neuropsychiatr Dis Treat 2006;2:583-5. 
  61. Omi T, Riku K, Fukumoto M, Kanai K, Omura Y, Takada H, et al. Paliperidone induced hypoglycemia by increasing insulin secretion. Case Rep Psychiatry 2016 Jul 10 [Epub ahead of print]. doi: 10.1155/2016/1805414. 
  62. Omi T, Riku K, Fukumoto M, Kanai K, Omura Y, Takada H, et al. Paliperidone induced hypoglycemia by increasing insulin secretion. Case Rep Psychiatry 2016;2016:1805414. 
  63. Cho SJ, Lee SA. Quetiapine-induced severe hypoglycemia in patient without diabetes mellitus: a case report. Ann Geriatr Med Res 2019;23:35-7. 
  64. Nagamine T. Severe hypoglycemia associated with risperidone. Psychiatry Clin Neurosci 2016;70:421. 
  65. Mondal S, Saha I, Das S, Ganguly A, Ghosh A, Kumar Das A. Oral aripiprazole-induced severe hypoglycemia. Ther Drug Monit 2012;34:245-8. 
  66. Couto J, Dos Santos LP, Mendes T, Lopez R. Life-threatening hypoglycemia attributable to haloperidol in a patient with schizophrenia. Braz J Psychiatry 2019;41:190-1. 
  67. Kim H, Toyofuku Y, Lynn FC, Chak E, Uchida T, Mizukami H, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010;16:804-8. 
  68. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73.